Current Vascular Pharmacology

Scope & Guideline

Pioneering Insights in Pharmacology and Cardiology

Introduction

Welcome to the Current Vascular Pharmacology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Current Vascular Pharmacology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1570-1611
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2003 to 2024
AbbreviationCURR VASC PHARMACOL / Current Vascular Pharmacology
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

Current Vascular Pharmacology focuses on the intersection of vascular health and pharmacological interventions, addressing a wide range of cardiovascular diseases and their management through innovative therapeutic strategies.
  1. Cardiovascular Disease Management:
    The journal emphasizes research on the prevention, diagnosis, and treatment of cardiovascular diseases, including heart failure, atrial fibrillation, and peripheral artery disease.
  2. Pharmacological Innovations:
    There is a strong focus on new and existing pharmacological agents, including statins, antiplatelet therapies, and novel molecules, assessing their efficacy and safety in various patient populations.
  3. Molecular and Cellular Mechanisms:
    Research often delves into the underlying molecular and cellular mechanisms of vascular diseases, exploring pathways such as oxidative stress, inflammation, and metabolic dysfunction.
  4. Clinical Outcomes and Risk Assessment:
    The journal publishes studies that evaluate clinical outcomes related to cardiovascular interventions, risk factors, and the impact of comorbidities on vascular health.
  5. Preventive Strategies:
    A significant portion of the journal’s output is dedicated to preventive measures in cardiovascular health, including lifestyle modifications, dietary impacts, and pharmacological prevention.
The landscape of research within Current Vascular Pharmacology is evolving, with several themes gaining prominence in recent publications.
  1. Integrative Approaches to Cardiovascular Health:
    There is a growing trend towards integrative studies that examine the interplay between various cardiovascular risk factors, comorbidities, and their collective impact on vascular health.
  2. Novel Biomarkers and Therapeutic Targets:
    Research is increasingly focusing on identifying novel biomarkers and therapeutic targets, such as microRNAs and various signaling pathways, which could lead to innovative treatment options.
  3. Impact of Lifestyle and Dietary Interventions:
    Studies exploring the effects of lifestyle changes, such as diet and exercise, on cardiovascular health are gaining traction, reflecting a shift towards preventive cardiology.
  4. Pharmacogenomics in Cardiovascular Therapy:
    Emerging themes include the application of pharmacogenomic data to optimize cardiovascular drug therapy, enhancing the safety and efficacy of treatments for diverse populations.
  5. Long-term Outcomes and Quality of Life Studies:
    There is an increasing emphasis on long-term outcomes and quality of life in cardiovascular disease management, with a focus on understanding how interventions impact patients over time.

Declining or Waning

While Current Vascular Pharmacology continues to thrive in many research areas, certain themes have seen a noticeable decline in focus over recent years.
  1. Traditional Risk Factors without Novel Insights:
    Research centered solely on traditional cardiovascular risk factors, such as hypertension and hyperlipidemia, without exploring novel insights or innovative management strategies, has become less prevalent.
  2. Aging and Vascular Disease:
    While still relevant, studies specifically linking aging as a singular factor in vascular disease have decreased, possibly due to a shift towards more integrative approaches that consider multiple comorbidities.
  3. Single-Agent Studies in Pharmacotherapy:
    Research focusing exclusively on the effects of single-agent pharmacotherapy, rather than combination therapies or multifaceted approaches, appears to have waned in favor of more comprehensive treatment strategies.
  4. Basic Science without Clinical Relevance:
    Basic science studies that do not translate into clinical applications or implications for patient care are being published less frequently, as the journal increasingly emphasizes clinical relevance.

Similar Journals

Aktuelle Kardiologie

Connecting experts to foster innovation in heart health.
Publisher: GEORG THIEME VERLAG KGISSN: 2193-5203Frequency: 6 issues/year

Aktuelle Kardiologie is a premier journal in the field of cardiology, published by GEORG THIEME VERLAG KG. With its ISSN 2193-5203 and E-ISSN 2193-5211, it serves as an essential resource for cardiologists, researchers, and healthcare professionals who seek to stay abreast of the latest developments in cardiovascular medicine. Although currently not open access, the journal provides comprehensive insights through its rigorous peer-review process, ensuring high-quality content for its readers. Located in Stuttgart, Germany, the journal’s objectives include fostering the exchange of innovative research, clinical findings, and expert opinions that can significantly enhance patient care and inspire further studies in cardiovascular health. In an era where cardiovascular diseases are a leading public health concern, Aktuelle Kardiologie remains a vital platform for disseminating critical knowledge and advancing the field.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Fostering collaboration in the realm of cardiovascular pharmacology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0160-2446Frequency: 12 issues/year

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

MOLECULAR PHARMACOLOGY

Illuminating the Pathways of Drug Mechanisms
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0026-895XFrequency: 12 issues/year

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

Diabetes & Vascular Disease Research

Bridging the gap between diabetes and cardiovascular wellness.
Publisher: SAGE PUBLICATIONS LTDISSN: 1479-1641Frequency: 6 issues/year

Diabetes & Vascular Disease Research is a leading academic journal dedicated to advancing the understanding and treatment of cardiovascular and metabolic diseases, particularly diabetes. Published by SAGE Publications Ltd in the United Kingdom, this journal serves as a key resource for researchers, clinicians, and students seeking to explore the intricate relationship between diabetes and vascular health. With an impressive Impact Factor and ranked in the Q2 quartile in prominent categories such as Cardiology, Endocrinology, and Internal Medicine, the journal provides a platform for high-quality, peer-reviewed research. Covering a broad range of topics from pathophysiology to therapeutic innovations, Diabetes & Vascular Disease Research plays a vital role in shaping contemporary discourse in the field. With contributions from leading experts and a commitment to disseminating valuable findings, this journal is a must-read for anyone involved in the fight against vascular complications arising from diabetes.

HEART AND VESSELS

Transforming Heart Health Through Scholarly Excellence
Publisher: SPRINGERISSN: 0910-8327Frequency: 12 issues/year

HEART AND VESSELS is a prominent peer-reviewed journal published by SPRINGER, dedicated to advancing the fields of cardiology and cardiovascular medicine. With its ISSN 0910-8327 and E-ISSN 1615-2573, this esteemed journal encompasses a broad range of topics pertinent to heart health, vascular function, and associated therapies, making it an essential resource for researchers, clinicians, and healthcare professionals alike. Based in Japan and operating since 1985, HEART AND VESSELS has consistently maintained a Q2 ranking in the 2023 category quartiles, highlighting its relevance and impact in the cardio domain. Although it does not offer open access, the journal ensures high-quality publications that contribute significantly to the academic and clinical understanding of cardiovascular health. With over three decades of continuous scholarly contribution, HEART AND VESSELS serves as a vital platform for disseminating cutting-edge research and fostering innovative practices in the management of cardiovascular diseases.

IJC Heart & Vasculature

Shaping the Future of Cardiovascular Medicine Together
Publisher: ELSEVIER IRELAND LTDISSN: Frequency: 4 issues/year

IJC Heart & Vasculature is a premier open-access journal published by Elsevier Ireland Ltd, dedicated to advancing research in the fields of cardiology and cardiovascular medicine. Since its inception in 2013, this journal has established itself as a valuable resource for clinicians, researchers, and students keen on exploring the latest developments in heart and vascular health. With an impressive impact factor and ranked within Q2 in its category (2023), IJC Heart & Vasculature has achieved a significant Scopus rank of #125 out of 387, placing it in the 67th percentile of cardiology journals. The journal not only emphasizes high-quality research but also promotes innovative studies that can shape clinical practices and improve patient outcomes. Researchers and professionals can access a plethora of peer-reviewed articles, original research, and comprehensive reviews that unravel the complexities of cardiovascular science. With a commitment to fostering open and impactful dialogue in the field, IJC Heart & Vasculature is poised to be an essential platform for knowledge exchange in the evolving landscape of cardiovascular research.

Anatolian Journal of Cardiology

Fostering Cardiovascular Excellence Since 2001.
Publisher: KARE PUBLISSN: 2149-2263Frequency: 12 issues/year

The Anatolian Journal of Cardiology, published by KARE PUBL, stands as a vital resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 2149-2263 and E-ISSN 2149-2271, this Open Access journal has been fostering the dissemination of critical research since 2001, ensuring that high-quality content is freely available to a global audience. Based in Turkey, the journal aims to bridge gaps in cardiological knowledge through rigorous peer-reviewed articles that span a wide range of topics, from innovative clinical practices to groundbreaking research findings. While its current ranking places it in the Q3 category of cardiology journals, the Anatolian Journal of Cardiology continues to strive towards enhancing its impact, currently holding a Scopus rank of 236 out of 387. Researchers, practitioners, and students alike will find this journal an essential platform for keeping abreast of the latest developments in cardiovascular health.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Unraveling the complexities of heart health and medication.
Publisher: SAGE PUBLICATIONS INCISSN: 1074-2484Frequency: 6 issues/year

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

CARDIOVASCULAR RESEARCH

Pioneering discoveries in cardiology and physiology.
Publisher: OXFORD UNIV PRESSISSN: 0008-6363Frequency: 18 issues/year

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

VASCULAR MEDICINE

Transforming research into practice for superior vascular care.
Publisher: SAGE PUBLICATIONS LTDISSN: 1358-863XFrequency: 6 issues/year

Vascular Medicine is a premier academic journal for researchers and practitioners in the field of cardiovascular health, published by SAGE Publications Ltd. With an ISSN of 1358-863X and E-ISSN 1477-0377, this esteemed journal has been at the forefront of publishing quality research since its inception in 1992, with convergence extending to 2024. Ranked in the Q2 category for both Cardiology and Cardiovascular Medicine as well as for miscellaneous Medicine in 2023, it is recognized for its significant contributions to advancing knowledge and clinical practice within these domains. Its Scopus ranking situates it at #91 out of 387 in the field, reflecting its high impact and the relevance of its published research, which is crucial for addressing the challenges in vascular health today. Although it is not an open-access journal, Vascular Medicine remains dedicated to disseminating vital findings that bridge the gap between research and clinical application, making it an essential resource for medical researchers, healthcare professionals, and students alike.